Abstract
Opioids are frequently used to alleviate pain in patients with advanced medical illness; however, constipation that is at least in part mediated by activation of gastrointestinal µ-opioid receptors is a common complication of this treatment. Methylnaltrexone is a peripherally acting antagonist of µ-opioid receptors that selectively blocks peripheral receptors without affecting the effects of opioids mediated by central receptors. This commentary discusses the findings of a 2-week, double-blind, randomized, placebo-controlled trial that investigated the efficacy and safety of subcutaneous methylnaltrexone in relieving opioid-induced constipation in patients with advanced medical illness. Thomas et al. administered methylnaltrexone or a placebo to patients every other day for 2 weeks. There was a threefold increase in the proportion of patients with laxation within 4 h after methylnaltrexone administration compared with placebo (48% vs 15%, respectively). A 3-month, open-label extension phase demonstrated that methylnaltrexone efficacy was maintained. Patients reported gastrointestinal adverse effects but did not experience centrally mediated withdrawal symptoms or loss of analgesia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Sykes NP (1998) The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med 12: 375–382
Thomas J et al. (2008) Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 358: 2332–2343
Yuan CS and Foss JF (2000) Oral methylnaltrexone for opioid-induced constipation. JAMA 284: 1383–1384
Berde C and Nurko S (2008) Opioid side effects—mechanism-based therapy. N Engl J Med 358: 2400–2402
Delaney CP et al. (2007) Alvimopan, for postoperative ileus following bowel resection: a pooled analysis of phase III studies. Ann Surg 245: 355–363
Author information
Authors and Affiliations
Ethics declarations
Competing interests
J Foss is a stockholder/director of Progenics Pharmaceuticals and is a patent holder/applicant at University of Chicago.
Rights and permissions
About this article
Cite this article
Foss, J. How safe and effective is methylnaltrexone for the treatment of opioid-induced constipation in advanced illness?. Nat Rev Gastroenterol Hepatol 6, 12–13 (2009). https://doi.org/10.1038/ncpgasthep1315
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncpgasthep1315